C. diff: The Hospital Bug That FMT Can Cure

Clostridioides difficile — known simply as C. diff — is one of the most dreaded infections in modern medicine. It causes debilitating diarrhoea, severe abdominal pain, and in its most severe form, life-threatening colitis that can require emergency surgery. It is the most common cause of healthcare-associated diarrhoea worldwide, and its capacity to recur after treatment makes it one of the most psychologically and physically exhausting infections a patient can endure.

But there is good news — genuinely transformative good news. Faecal Microbiota Transplantation (FMT) cures recurrent C. diff in over 90 percent of cases, making it one of the most effective treatments in all of medicine. At our clinic, our success rate is 98 percent.

Understanding C. diff: Why It Keeps Coming Back

C. diff is a spore-forming bacterium. When antibiotics disrupt the normal gut microbiome — killing the beneficial bacteria that keep C. diff in check — dormant spores can germinate, multiply, and produce toxins that damage the colonic lining. This is why C. diff infection almost always follows antibiotic use, whether for a urinary tract infection, a dental procedure, or anything else.

The cruel irony is that the standard treatment for C. diff is more antibiotics — typically vancomycin or fidaxomicin. While these drugs kill the active C. diff bacteria, they do nothing to restore the depleted microbiome. The spores remain. And when the antibiotics are stopped, the cycle often begins again.

Recurrence rates after a first episode of C. diff are approximately 25 to 30 percent. After a first recurrence, the risk of subsequent recurrence jumps to 40 to 60 percent. Some patients experience four, five, or more recurrences, each one chipping away at their quality of life, nutritional status, and psychological wellbeing. These patients are often housebound, afraid to eat, afraid to leave the house, and profoundly demoralised.

Why FMT Works So Well for C. diff

FMT addresses the fundamental problem that antibiotics cannot: the broken microbiome. By transplanting a diverse, healthy microbial community from a screened donor, FMT restores the colonisation resistance that prevents C. diff spores from germinating. It is not just treating the infection — it is fixing the ecosystem that allowed the infection to take hold.

The evidence supporting FMT for recurrent C. diff is among the strongest in gastroenterology. Multiple randomised controlled trials have demonstrated superiority over antibiotic therapy alone, with cure rates consistently above 90 percent. International guidelines from the American Gastroenterological Association and the Australasian Society of Infectious Diseases now recommend FMT for patients with recurrent C. diff after failure of standard antibiotic therapy.

In our practice, the results have been extraordinary. Our 98 percent cure rate reflects both the quality of our donor screening program — which includes rigorous microbiome diversity assessment — and the precision of our delivery protocols. For patients who have suffered through multiple recurrences, the transformation is often dramatic: resolution of diarrhoea within days, return of normal energy levels within weeks, and a restoration of confidence and quality of life that many had given up hoping for.

The Patient Experience

We understand that the concept of FMT can be confronting for some patients. The idea of receiving processed stool from a donor is not intuitive, and many patients arrive at our clinic with a mixture of hope and apprehension. We take the time to explain the process thoroughly, answer every question, and ensure that patients feel informed and comfortable before proceeding.

The procedure itself is straightforward. Depending on the clinical scenario, FMT can be delivered via fresh enema, capsule, or transcolonic infusion. The choice of delivery method is tailored to the individual patient. The procedure is well tolerated, and most patients can return to normal activities quickly.

Side effects are generally mild: some bloating, mild cramping, or a temporary change in bowel habits is common in the first few days. Serious adverse events are rare, particularly with the stringent donor screening protocols we employ.

We provide comprehensive education before and after FMT, helping patients understand what to expect and how to optimise their recovery. Patients are advised to expect changes in bowel habits as the transplanted microbiome establishes itself — these changes are expected and typically indicative of successful engraftment rather than complications. We also counsel patients on gradual diet liberalisation after FMT, typically starting with a low-residue diet and progressively reintroducing fibre-rich foods over two to three weeks as the microbiome stabilises.

Beyond Acute Treatment: Preventing Recurrence

For patients at high risk of recurrence — such as those with multiple prior episodes, ongoing need for antibiotics for other conditions, or significant comorbidities — we may recommend an extended FMT program rather than a single treatment. This ensures sustained engraftment of the donor microbiome and provides a more durable restoration of colonisation resistance.

Our extended programs typically run over two to three months, with multiple FMT administrations spaced strategically. This approach is particularly valuable for patients whose recurrence is driven by ongoing antibiotic exposure for other conditions. By repeatedly inoculating with healthy donor bacteria, we help maintain a colonised microbiome that resists C. diff even during courses of antibiotics for unrelated infections.

We also work with patients on strategies to support their restored microbiome after FMT. This includes guidance on diet — emphasising prebiotic fibres that nourish the transplanted bacteria — judicious antibiotic use (avoiding unnecessary courses whenever possible), adequate sleep and stress management to support immune and gut function, and ongoing monitoring to ensure that the therapeutic gains are maintained. Some patients benefit from periodic microbiome testing at three and six months post-FMT to confirm sustained engraftment.

When to Consider FMT for C. diff

Current guidelines recommend FMT after two or more recurrences of C. diff that have failed to respond to standard antibiotic therapy. However, there is growing evidence and clinical sentiment that earlier FMT — even after a first recurrence — may be beneficial, particularly in older or frailer patients for whom repeated episodes carry significant morbidity.

If you or a family member has been battling recurrent C. diff infection, we strongly encourage a specialist consultation. FMT is not experimental for this indication — it is evidence-based, guideline-recommended, and in our experience, profoundly effective.

The donor screening for our C. diff FMT program is particularly rigorous. We screen for C. difficile itself (obviously), but also for all other potential enteropathogens: parasites, pathogenic bacteria, and viruses. We also perform comprehensive microbiome sequencing to ensure that the donor's gut flora is not just free of infection, but rich in diversity and microbial biomass. The goal is to transplant a robust, competitive ecosystem that will quickly establish itself in the recipient's colon and crowd out any remaining C. difficile spores before they have a chance to germinate.

For patients at highest recurrence risk — such as those with multiple prior episodes, advanced age, significant immunocompromise, or ongoing need for broad-spectrum antibiotics — we recommend our extended FMT programs. These involve multiple administrations over two to three months, building and reinforcing a resilient donor microbiome that can survive the inevitable insults from future antibiotic exposure. This approach has transformed outcomes in our most challenging patients.

Our follow-up protocols are comprehensive. Patients are monitored closely after FMT with regular symptom assessments and repeat microbiome testing at strategic intervals (typically 3 and 6 months post-FMT) to confirm sustained engraftment of the donor bacteria. We also educate patients on strategies to protect their restored microbiome: minimising unnecessary antibiotic use, maintaining adequate dietary fibre to feed the beneficial bacteria, managing stress effectively, and ensuring good sleep — all factors that support microbiome stability.

For patients trapped in the cycle of recurrent C. diff, FMT is not just a treatment. It is a cure — and it works in 98 percent of cases.

Living with recurrent C. diff is exhausting and isolating. But the solution exists, it is available, and it works. We are here to help.